Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The Сompany also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its prodcuts, include Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Company Growth (employees)
Indianapolis, US
Size (employees)
41,975 (est)
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US

Key People/Management at Eli Lilly

David Ricks

David Ricks

President and Chief Executive Officer
Josh Smiley

Josh Smiley

Susan Mahony

Susan Mahony

Senior Vice President and President Oncology
Stephen Fry

Stephen Fry

Senior Vice President, Human Resources and Diversity
Enrique Conterno

Enrique Conterno

President, LillyUSA
Melissa Barnes

Melissa Barnes

Chief Ethics and Compliance Officer
Alfonso Zulueta

Alfonso Zulueta

President, International
Jeffrey Simmons

Jeffrey Simmons

Senior Vice President

Eli Lilly Office Locations

Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 2 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Toronto, CA
3650 Danforth Ave
Windlesham, GB
Erl Wood Manor Sunninghill Road
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe

Eli Lilly Financials and Metrics

Eli Lilly Financials

Eli Lilly's revenue was reported to be $21.2 b in FY, 2016 which is a 6% increase from the previous period.

Revenue (FY, 2016)

21.2 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

15.6 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

2.7 b

Market capitalization (13-Nov-2017)

87.5 b
Eli Lilly's current market capitalization is $87.5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


23.1 b19.6 b20 b21.2 b

Revenue growth, %


Cost of goods sold

4.9 b4.9 b5 b5.7 b

Gross profit

18.2 b14.7 b14.9 b15.6 b
USDFY, 2013FY, 2014FY, 2015FY, 2016


3.8 b3.9 b3.7 b4.6 b

Accounts Receivable

588.4 m566.7 m558.6 m736.9 m


2.9 b2.7 b3.4 b3.6 b

Current Assets

13.1 b12.2 b12.6 b15.1 b
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7 b2.4 b2.4 b2.7 b

Cash From Operating Activities

5.7 b4.4 b2.8 b4.9 b

Purchases of PP&E

(1 b)(1.2 b)(1.1 b)(1 b)

Cash From Investing Activities

(2.1 b)(3.9 b)26.8 m(3.1 b)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017
Show all financial metrics

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Projects in R&D Pipeline


Phase III Trials

Show all operating metrics

Eli Lilly Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
CoLucid PharmaceuticalsJanuary 18, 2017$960 m
Novartis Animal HealthApril 22, 2014$5.4 b
Avid RadiopharmaceuticalsNovember 08, 2010$800 m
Alnara PharmaceuticalsJuly 02, 2010$280 m
Imclone SystemsOctober 06, 2008$6.5 b

Eli Lilly Market Value History

Eli Lilly Median Salaries

Source: 117 public H-1B filings from Eli Lilly

Eli Lilly's Web-traffic and Trends

Eli Lilly Online and Social Media Presence

Eli Lilly News and Updates

Eli Lilly counts up 2,300 early retirements in $500M cost-cutting drive

Eli Lilly has persuaded 2,300 employees to take early retirement as part of a companywide streamlining designed to save $500 million. With those settled, the company says it's "on track to achieve" the 3,500 job cuts it outlined in September, with some facilities closing entirely.

As Eli Lilly moves some marketing in-house, should ad agencies brace for fallout?

Eli Lilly is moving to a new marketing model as part of its push to manage expenses, but what does that mean for its advertising and marketing agency partners? So far, no one is saying exactly, but it almost certainly means less work as Lilly looks to bring more of the traditional agency of record s…

U.K. Supreme Court hands Eli Lilly big win in Alimta EU patent battle

The U.K. Supreme Court has handed Eli Lilly a huge patent victory for its cancer drug Alimta in a battle with Actavis, protecting some European sales of the blockbuster for another four years. It also represents a stunning loss for Actavis, now owned by Teva, which launched its generic several years…

Eli Lilly's Cyramza fuels expansion quest with positive bladder cancer showing

Eli Lilly’s had mixed results in its quest to expand cancer blockbuster hopeful Cyramza. But the data from its latest attempt, this time in bladder cancer, look good.

Eli Lilly Company Life and Culture

You may also be interested in